This clinical trial evaluates remotely delivered, community-aligned weight loss interventions in Latina breast cancer survivors. Breast cancer is the second leading cause of cancer death among women in the US. There are population differences in breast cancer mortality, based on specific risk factors, including obesity. Cancer is the leading cause of death among Latinos, and among Latinas, breast cancer is the leading cause of cancer death. An estimated 80% of Latinas in the United States have overweight/obesity, which is associated with poorer breast cancer outcomes. However, few, if any, effective interventions exist to promote and maintain weight loss in Latina breast cancer survivors. The development of an adaptive program that provides survivors with the support they need, as opposed to what is typically available, to improve breast cancer survivorship.
Biologically female
Age >= 18 years
Self-identifies Hispanic/Latina
Able to read and write in Spanish and/or English
Body mass index (BMI) < 27 kg/m² at time of baseline data collection
Diabetic with current use of insulin or sulfonylurea medications (note: current use of metformin is allowed)
Use of glucagon-like peptide-1 (GLP1) receptor agonist medications reported at baseline
Current use of cytotoxic chemotherapy medications (e.g., capecitabine) or drug-antibody conjugates (e.g., trastuzumab emtansine [T-DM1], trastuzumab deruxtecan [T-DXd])
6
Treatment groupsSee each treatment group below.
Fred Hutchinson Cancer Center
Lead sponsor
National Cancer Institute (NCI)
Collaborator